W
Won Ki Kang
Researcher at Samsung Medical Center
Publications - 385
Citations - 18420
Won Ki Kang is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Cancer & Capecitabine. The author has an hindex of 59, co-authored 368 publications receiving 14746 citations. Previous affiliations of Won Ki Kang include Sungkyunkwan University & Samsung.
Papers
More filters
Journal ArticleDOI
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Yung Jue Bang,Yoon-Koo Kang,Won Ki Kang,Narikazu Boku,Hyun Cheol Chung,Jen-Shi Chen,Toshihiko Doi,Yan Sun,Lin Shen,Shukui Qin,Wai Tong Ng,Jennifer M. Tursi,Maria Jose Lechuga,Dongrui Ray Lu,Ana Ruiz-Garcia,Alberto Sobrero +15 more
TL;DR: The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunit inib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.
Journal ArticleDOI
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
Suling J. Lin,Johann A. Gagnon-Bartsch,Iain Beehuat Tan,Sophie Earle,Louise Ruff,Katherine J Pettinger,Bauke Ylstra,Nicole C.T. van Grieken,Sun Young Rha,Hyun Cheol Chung,Ju Seog Lee,Jae Ho Cheong,Sung Hoon Noh,Toru Aoyama,Yohei Miyagi,Akira Tsuburaya,Takaki Yoshikawa,Jaffer A. Ajani,Alex Boussioutas,Alex Boussioutas,Khay Guan Yeoh,Wei Peng Yong,Jimmy Bok Yan So,Jeeyun Lee,Won Ki Kang,Sung Joon Kim,Yoichi Kameda,Tomio Arai,Axel zur Hausen,Terence P. Speed,Terence P. Speed,Heike I. Grabsch,Heike I. Grabsch,Patrick Tan +33 more
TL;DR: It is suggested that Asian and non-Asian GCs exhibit distinct tumour immunity signatures related to T-cell function, and these differences may influence geographical differences in clinical outcome, and the design of future trials particularly in immuno-oncology.
Journal ArticleDOI
Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.
Jeeyun Lee,Yeon Hee Park,Won Seog Kim,Seung-Sook Lee,Baek-Yeol Ryoo,Sung Hyun Yang,Keon Woo Park,Jung Hoon Kang,Joon Oh Park,Se-Hoon Lee,Kihyun Kim,Chul Won Jung,Young Suk Park,Young-Hyuck Im,Won Ki Kang,Mark Hong Lee,Young Hyeh Ko,Yong Chan Ahn,Keunchil Park +18 more
TL;DR: The EUNKTL group in this study had advanced stage at diagnosis, higher LDH, higher IPI score, poorer performance and inferior response to the anthracycline-based chemotherapy with statistical significance, and there was a significant difference in survival rate.
Journal ArticleDOI
Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma
Hye Jong Song,Amitabh Srivastava,Jeeyun Lee,Yun Soo Kim,Kyoung-Mee Kim,Won Ki Kang,Min-Ji Kim,Seonwoo Kim,Cheol Keun Park,Sung Kim +9 more
TL;DR: The definition of LELC should be expanded to include EBV-associated GCs with CLR because these have a prognosis similar to L ELC and are likely to have a better survival rate than other GCs.
Journal ArticleDOI
Malignant obstruction of gastric outlet and duodenum: palliation with flexible covered metallic stents.
Kwang Bo Park,Young Soo Do,Won Ki Kang,Sung Wook Choo,Yoon Hee Han,Soo Won Suh,Soon Jin Lee,Kil Sun Park,In Wook Choo +8 more
TL;DR: Flexible covered metallic stent placement can be useful for palliation in patients with malignant obstruction of the gastric outlet or duodenum with self-expandable flexible covered metallicStents.